Touch Medical Media coverage of data presented at EADV 2021:
It was a pleasure to speak with Prof. John E Harris (University of Massachusetts Medical School, Worcester, MA, USA) about the use of JAK inhibitors in vitiligo, what we have learned from their discontinuation and how this has helped drive the development of IL-15-targeted therapies.
His presentation entitled ‘Vitiligo: from topical JAK inhibitors to anti-IL15R’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021
Questions
- Could you tell us a little about current and emerging JAK inhibitors in the management of vitiligo? (0:12)
- What has been the impact of ruxolitinib on the treatment of vitiligo, and what is known about the effect of discontinuing treatment? (1:18)
- What have we learned about resident memory CD8 T cells and how might this cell subset be targeted in future therapeutic approaches? (2:29)
Disclosures: Prof. John E Harris has acted as a consultant and investigator for Pfizer, Genzyme/ Sanofi, Incyte, Rheos Medicines, Sun Pharmaceutical, LEO Pharma, Villaris Therapeutics, Dermavant and TeVido BioDevices; a consultant for AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, NIRA Biosciences, Admirx, Granular Therapeutics and Platelet BioGenesis; has Equity in TeVido Biodevices, Rheos, Villaris Therapeutics, NIRA Biosciences and is Founder of Villaris Therapeutics and NIRA Biosciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
